Pompe disease is a rare genetic condition in which the body can’t properly break down a stored sugar called glycogen. It affects roughly 2 out of every 100,000 live births worldwide. The core problem is a missing or deficient enzyme that normally works inside cells to convert glycogen into usable glucose. Without enough of this enzyme, glycogen builds up inside cellular compartments called lysosomes, gradually damaging muscle tissue throughout the body, especially the heart and the muscles used for breathing and movement.
How Pompe Disease Works in the Body
Every cell has small recycling centers called lysosomes that break down molecules the cell no longer needs. One of the enzymes inside lysosomes is responsible for chopping glycogen (a stored form of sugar) into glucose. In Pompe disease, this enzyme is either absent or produced in very low amounts due to mutations in the GAA gene.
When the enzyme is missing, glycogen accumulates inside lysosomes, causing them to swell. Over time, these bloated lysosomes crowd out healthy cell structures and interfere with normal muscle function. Although glycogen builds up in many tissues, the damage hits hardest in cardiac muscle and skeletal muscle, which is why the disease primarily shows up as heart problems, progressive weakness, and breathing difficulties.
Infantile-Onset Pompe Disease
The most severe form, classic infantile-onset Pompe disease, appears within the first few months of life. Infants typically have very little or no working enzyme (less than 1% of normal levels). Symptoms include severe muscle weakness, poor muscle tone, an enlarged liver, and heart defects. Babies often have trouble feeding, fail to gain weight at normal rates, and develop breathing problems early. The heart enlarges rapidly, and without treatment, this form leads to heart failure and death within the first year of life.
A second, slightly less severe form called non-classic infantile-onset Pompe disease usually appears by age 1. These children experience delayed motor milestones like rolling over and sitting, along with progressive muscle weakness. The heart may be enlarged, but heart failure is less common. Breathing problems are the primary threat, and most children with this form survive only into early childhood without intervention.
Late-Onset Pompe Disease
Late-onset Pompe disease is the more common form, with a global birth prevalence of about 2.4 per 100,000 live births compared to 1.0 per 100,000 for the infantile-onset type. It can appear anywhere from childhood to as late as the sixth or seventh decade of life. People with this form retain some enzyme activity, typically 2% to 40% of normal levels, which explains the slower progression.
The hallmark is progressive weakness in the muscles closest to the trunk: hips, thighs, shoulders, and the muscles of the torso. Many people first notice difficulty climbing stairs, getting up from a chair, or keeping up during physical activity. Breathing muscles are often affected more than you’d expect given the level of limb weakness, and some people develop respiratory insufficiency before they notice significant trouble walking. Over time, breathing problems can progress to respiratory failure, and some individuals eventually need a wheelchair. Unlike the infantile forms, late-onset Pompe disease rarely involves the heart.
How Pompe Disease Is Inherited
Pompe disease follows an autosomal recessive pattern, meaning a child must inherit a faulty copy of the GAA gene from both parents to develop the condition. Parents who each carry one mutated copy typically have no symptoms themselves. When both parents are carriers, each pregnancy carries a 25% chance of producing a child with Pompe disease. The specific mutations a person inherits play a large role in how much enzyme the body can still produce, which in turn influences whether the disease appears in infancy or later in life.
Diagnosis
Pompe disease is diagnosed by measuring the activity of the affected enzyme. A dried blood spot test can serve as an initial screen, and if enzyme activity comes back low, genetic testing of the GAA gene confirms the diagnosis. Complete enzyme deficiency (less than 1% of normal) points to infantile-onset disease, while partial deficiency (2% to 40%) is associated with the late-onset form.
In 2015, Pompe disease was added to the Recommended Uniform Screening Panel (RUSP) for newborns in the United States, following a 2013 advisory committee vote. Newborn screening has been rolling out state by state since then, which means more cases are being caught before symptoms appear. Early detection matters because treatment works best when started before significant muscle damage has occurred.
For older children and adults, late-onset Pompe disease is notoriously difficult to diagnose. Symptoms like gradual muscle weakness and unexplained breathing trouble overlap with many other conditions, and patients often see multiple specialists, including neurologists, pulmonologists, rheumatologists, and orthopedic doctors, before the correct diagnosis is made. The average diagnostic delay can stretch for years.
Treatment With Enzyme Replacement Therapy
The first enzyme replacement therapy (ERT) for Pompe disease was approved by the FDA in 2006, marking a turning point for patients. ERT works by delivering a manufactured version of the missing enzyme through intravenous infusions, typically given every two weeks. The enzyme enters cells and helps clear the accumulated glycogen from lysosomes.
A newer version of ERT was later developed to improve how efficiently cells take up the replacement enzyme. In a clinical trial that followed late-onset patients for 145 weeks, those on the newer therapy maintained improvements in lung function and gained an average of about 21 meters on a six-minute walk test compared to baseline. Patients who switched from the older therapy to the newer one during the trial also maintained their lung function and showed continued improvement in breathing muscle strength.
ERT does not cure Pompe disease, and results vary. It tends to be most effective when started early, particularly in infants, where it can prevent or delay the severe heart damage that would otherwise be fatal. In late-onset patients, ERT generally stabilizes or slows the decline in muscle and respiratory function rather than reversing it completely.
Living With Pompe Disease
Managing Pompe disease involves more than infusions. Most patients work with a team of specialists. Pulmonologists monitor and manage breathing function, which may eventually require ventilatory support, especially during sleep. Physical therapists help maintain mobility and muscle strength. Nutritional support and occupational therapy round out care for many patients, particularly children with the infantile forms.
For adults with late-onset disease, the pace of progression varies widely. Some people remain independently mobile for decades, while others experience a faster decline. Regular monitoring of lung capacity and muscle strength helps guide treatment decisions and catch changes before they become emergencies. Respiratory function, in particular, needs close tracking because breathing muscles can weaken significantly before a person feels obviously short of breath during everyday activities.